Are inhaled vasodilators useful in acute lung injury and acute respiratory distress syndrome?

Respiratory Care

Volumn 55, Issue 2, 2010, Pages 144-157

  Siobal, Mark S ^a   Hess, Dean R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Inhaled nitric oxide; Prostacyclin; Pulmonary hypertension

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; GUANYLATE CYCLASE ACTIVATOR; ILOPROST; MILRINONE; NEUROMUSCULAR BLOCKING AGENT; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OXYGEN; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN E1; VASODILATOR AGENT;

ACUTE HEART FAILURE; ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; AEROSOL; AGITATION; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG COST; DYSRHYTH; HEART ARRHYTHMIA; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXEMIA; HYPOXIA; LUNG INSUFFICIENCY; NEBULIZER; NONHUMAN; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; THROMBUS;

ACUTE LUNG INJURY; ADMINISTRATION, INHALATION; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; POSITIVE-PRESSURE RESPIRATION; PROSTAGLANDINS I; RESPIRATORY DISTRESS SYNDROME, ADULT; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 76249099170     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (132)

1. Siobal MS. Pulmonary vasodilators. Respir Care 2007;52(7):885-899.
2. Putensen C, Hormann C, Kleinsasser A, Putensen-Himmer G. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998;157(6 Pt 1):1743-1747.
3. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328(6):399-405.
4. Radermacher P, Santak B, Wust HJ, Tarnow J, Falke KJ. Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: effects on pulmonary capillary pressure and ventilation-perfusion distributions. Anesthesiology 1990; 72(2):238-244.
5. Melot C, Dechamps P, Hallemans R, Decroly P, Mols P. Enhancement of hypoxic pulmonary vasoconstriction by low dose almitrine bismesylate in normal humans. Am Rev Respir Dis 1989;139(1):111-119.
6. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342(18):1334-1349.
7. Tomashefski JF Jr. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med 2000;21(3):435-466.
8. Tomashefski JF Jr, Davies P, Boggis C, Greene R, Zapol WM, Reid LM. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol 1983;112(1):112-126.
9. Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. N Engl J Med 2005;353(25):2683-2695.
10. Haraldsson SA, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001;93(6):1439-1445, table of contents.
11. Gong F, Shiraishi H, Kikuchi Y, Hoshina M, Ichihashi K, Sato Y, et al. Inhalation of nebulized nitroglycerin in dogs with experimental pulmonary hypertension induced by U46619. Pediatr Int 2000; 42(3):255-258.
12. Gong F, Shiraishi H, Momoi MY. The effects of inhalation of nebulized nitroglycerin on dogs with experimental pulmonary hypertension induced by U46619. Chin Med J (Engl) 2000;113(5):475-476.
13. Goyal P, Kiran U, Chauhan S, Juneja R, Choudhary M. Efficacy of nitroglycerin inhalation in reducing pulmonary arterial hypertension in children with congenital heart disease. Br J Anaesth 2006; 97(2):208-214.
14. Mitchell GK. Nitroglycerine by inhaler as treatment for migraine causing cerebral ischaemia. Med J Aust 1999;171(6):336.
15. Yurtseven N, Karaca P, Kaplan M, Ozkul V, Tuygun AK, Aksoy T, et al. Effect of nitroglycerin inhalation on patients with pulmonary hypertension undergoing mitral valve replacement surgery. Anesthesiology 2003;99(4):855-858.
16. Siobal M. Aerosolized prostacyclins. Respir Care 2004;49(6):640-652.
17. Palhares D. Nebulized sodium nitroprusside. J Pediatr 2004;145(4):569.
18. Jacobs BR, Brilli RJ, Ballard ET, Passerini DJ, Smith DJ. Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury. Am J Respir Crit Care Med 1998;158(5 Pt 1):1536-1542.
19. Schutte H, Grimminger F, Otterbein J, Spriestersbach R, Mayer K, Walmrath D, et al. Efficiency of aerosolized nitric oxide donor drugs to achieve sustained pulmonary vasodilation. J Pharmacol Exp Ther 1997;282(2):985-994.
20. Xia HP, Huang GY, Zhu JX, Sun B. Effect of inhalation of nebulized NO donor substance on acute hypoxic lung injury in newborn piglets. Chin Med J (Engl) 2008;121(17):1622-1626.
21. Aubin MC, Laurendeau S, Mommerot A, Lamarche Y, Denault A, Carrier M, et al. Differential effects of inhaled and intravenous sildenafil in the prevention of the pulmonary endothelial dysfunction due to cardiopulmonary bypass. J Cardiovasc Pharmacol 2008; 51(1):11-17.
22. Ichinose F, Adrie C, Hurford WE, Bloch KD, Zapol WM. Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology 1998;88(2):410-416.
23. Ichinose F, Erana-Garcia J, Hromi J, Raveh Y, Jones R, Krim L, et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001;29(5):1000-1005.
24. Deja M, Busch T, Wolf S, Donaubauer B, Petersen B, Skomrock J, et al. Inhalation of the endothelin-A receptor antagonist LU-135252 at various doses in experimental acute lung injury. J Cardiovasc Pharmacol Res Commun 2004;44(1):S151-S155.
25. Donaubauer B, Busch T, Lachmann R, Deja M, Petersen B, Francis R, et al. Low-dose inhalation of an endothelin-A receptor antagonist in experimental acute lung injury: ET-1 plasma concentration and pulmonary inflammation. Exp Biol Med (Maywood) 2006; 231(6):960-966.
26. Deja M, Wolf S, Busch T, Petersen B, Jaghzies U, Boemke W, et al. The inhaled ET(A) receptor antagonist LU-135252 acts as a selective pulmonary vasodilator. Clin Sci (Lond) 2002;103(48):S21-S24.
27. Evgenov OV, Kohane DS, Bloch KD, Stasch JP, Volpato GP, Bellas E, et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 2007; 176(11):1138-1145.
28. Lowson SM. Inhaled alternatives to nitric oxide. Crit Care Med 2005;33(3):S188-S195.
29. Steudel W, Hurford WE, Zapol WM. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology 1999;91(4):1090-1121.
30. Van Heerden PV, Blythe D, Webb SA. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS: a pilot study. Anaesth Intensive Care 1996;24(5):564-568.
31. Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome.AmJ Respir Crit Care Med 1996;153(3):991-996.
32. Zwissler B, Kemming G, Habler O, Kleen M, Merkel M, Haller M, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996;154(6 Pt 1):1671-1677.
33. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006(4):CD000399.
34. Kermode J, Butt W, Shann F. Comparison between prostaglandin E1 and epoprostenol (prostacyclin) in infants after heart surgery. Br Heart J 1991;66(2):175-178.
35. Walmrath D, Schermuly R, Pilch J, Grimminger F, Seeger W. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J 1997;10(5):1084-1092.
36. Szczeklik A, Gryglewski RJ, Nizankowska E, Nizankowsk iR, Musial J. Pulmonary and anti-platelet effects of intravenous and inhaled prostacyclin in man. Prostaglandins 1978;16(6):651-659.
37. Kleen M, Habler O, Hofstetter C, Pusch R, Mueller M, Welte M, et al. Efficacy of inhaled prostanoids in experimental pulmonary hypertension. Crit Care Med 1998;26(6):1103-1109.
38. Leung PC, Chan MY, Roberts MB. The use of prostaglandins as local antithrombotic agents in microvascular surgery. Br J Plast Surg 1981;34(1):38-40.
39. Siobal MS, Kallet RH, Pittet JF, Warnecke EL, Kraemer RW, Venkayya RV, et al. Description and evaluation of a delivery system for aerosolized prostacyclin. Respir Care 2003;48(8):742-753.
40. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322-329.
41. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124(9):820-824.
42. Sablotzk iA, Hentschel T, Gruenig E, Schubert S, Friedrich I, Mü-hling J, et al. Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur J Cardiothorac Surg 2002;22(5):746-752.
43. Kramm T, Eberle B, Guth S, Mayer E. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardiothorac Surg 2005;28(6):882-888.
44. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, et al. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003;24(4):356-365.
45. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ 2007; 334(7597):779.
46. Day RW, Allen EM, Witte MK. A randomized, controlled study of the 1-hour and 24-hour effects of inhaled nitric oxide therapy in children with acute hypoxemic respiratory failure. Chest 1997; 112(5):1324-1331.
47. Schwebel C, Beuret P, Perdrix JP, Jospe R, Duperret S, Fogliani J, et al. Early inhaled nitric oxide inhalation in acute lung injury: results of a double-blind randomized study [abstract]. Intensive Care Med 1997; 23(Suppl. 1):S2.
48. Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 1998; 26(1):15-23.
49. Michael JR, Barton RG, Saffle JR, Mone M, Markewitz BA, Hillier K, et al. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med 1998;157(5 Pt 1)1372-1380.
50. Troncy E, Collet JP, Shapiro S, Guimond JG, Blair L, Ducruet T, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med 1998;157(5 Pt 1):1483-1488.
51. Dobyns EL, Anas NG, Fortenberry JD, Deshpande J, Cornfield DN, Tasker RC, et al. Interactive effects of high-frequency oscillatory ventilation and inhaled nitric oxide in acute hypoxemic respiratory failure in pediatrics. Crit Care Med 2002;30(11):2425-2429.
52. Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med 1999; 25(9):911-919.
53. Mehta S, Simms HH, Levy MM, Hill NS, Schwartz W, Nelson D, et al. Inhaled nitric oxide improves oxygenation acutely but not chronically in acute respiratory distress syndrome: a randomized, controlled trial. Journal of Applied Research 2001;1(2):73-84.
54. Park KJ, Lee YJ, Oh YJ, Lee KS, Sheen SS, Hwang SC. Combined effects of inhaled nitric oxide and a recruitment maneuver in patients with acute respiratory distress syndrome. Yonsei Med J 2003; 44(2):219-226.
55. Tsushima K, King LS, Aggarwal NR, De Gorordo A, D'Alessio FR, Kubo K. Acute lung injury review. Intern Med 2009;48(9): 621-630.
56. Schuster KM, Alouidor R, Barquist ES. Nonventilatory interventions in the acute respiratory distress syndrome. J Intensive Care Med 2008;23(1):19-32.
57. Busch T, Bercker S, Laudi S, Donaubauer B, Petersen B, Kaisers U. Inhaled nitric oxide for rescue treatment of refractory hypoxemia in ARDS patients. Anasthesiol Intensivmed Notfallmed Schmerzther 2008;43(11-12):778-783.
58. Deja M, Hommel M, Weber-Carstens S, Moss M, von Dossow V, Sander M, et al. Evidence-based therapy of severe acute respiratory distress syndrome: an algorithm-guided approach. J Int Med Res 2008;36(2):211-221.
59. Laudi S, Busch T, Bercker S, Donaubauer B, Kaisers U. Therapeutic options for patients with acute lung injury. Anasthesiol Intensivmed Notfallmed Schmerzther 2007;42(11):794-799.
60. Germann P, Braschi A, Della Rocca G, Dinh-Xuan AT, Falke K, Frostell C, et al. Inhaled nitric oxide therapy in adults: European expert recommendations. Intensive Care Med 2005;31(8):1029-1041.
61. Cranshaw J, Griffiths MJ, Evans TW. The pulmonary physician in critical care. Part 9: non-ventilatory strategies in ARDS. Thorax 2002;57(9):823-829.
62. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000;35(1):176-182.
63. Hsu CW, Lee DL, Lin SL, Sun SF, Chang HW. The initial response to inhaled nitric oxide treatment for intensive care unit patients with acute respiratory distress syndrome. Respiration 2008;75(3):288-295.
64. Bein T, Metz C, Keyl C, Sendtner E, Pfeifer M. Cardiovascular and pulmonary effects of aerosolized prostacyclin administration in severe respiratory failure using a ventilator nebulization system. J Cardiovasc Pharmacol 1996;27(4):583-586.
65. Jardin F, Vieillard-Baron A. Is there a safe plateau pressure in ARDS? The right heart only knows. Intensive Care Med 2007; 33(3):444-447.
66. Jardin F. Acute leftward septal shift by lung recruitment maneuver. Intensive Care Med 2005;31(9):1148-1149.
67. Vieillard-Baron A, Jardin F. Why protect the right ventricle in patients with acute respiratory distress syndrome? Curr Opin Crit Care 2003;9(1):15-21.
68. Vieillard-Baron A, Schmitt JM, Augarde R, Fellahi JL, Prin S, Page B, et al. Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosis. Crit Care Med 2001;29(8):1551-1555.
69. Dueck R. Alveolar recruitment versus hyperinflation: a balancing act. Curr Opin Anaesthesiol 2006;19(6):650-654.
70. Dhainaut JF, Brunet F. Right ventricular performance in adult respiratory distress syndrome. Eur Respir J Suppl 1990;11:490S-495S.
71. Thiel M, Chouker A, Ohta A, Jackson E, Caldwell C, Smith P, et al. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol 2005;3(6):e174.
72. Greyson CR. Pathophysiology of right ventricular failure. Crit Care Med 2008;36(1 Suppl):S57-65.
73. Woods J, Monteiro P, Rhodes A. Right ventricular dysfunction. Curr Opin Crit Care 2007;13(5):532-540.
74. Zapol WM, Snider MT. Pulmonary hypertension in severe acute respiratory failure. N Engl J Med 1977;296(9):476-480.
75. Leeman M. Pulmonary hypertension in acute respiratory distress syndrome. Monaldi Arch Chest Dis 1999;54(2):146-149.
76. Romand JA, Donald FA, Suter PM. Cardiopulmonary interactions in acute lung injury: clinical and prognostic importance of pulmonary hypertension. New Horiz 1994;2(4):457-462.
77. Villar J, Blazquez MA, Lubillo S, Quintana J, Manzano JL. Pulmonary hypertension in acute respiratory failure. Crit Care Med 1989;17(6):523-526.
78. Mebazaa A, Karpati P, Renaud E, Algotsson L. Acute right ventricular failure: from pathophysiology to new treatments. Intensive Care Med 2004;30(2):185-196.
79. Sibbald WJ, Driedger AA. Right ventricular function in acute disease states: pathophysiologic considerations. Crit Care Med 1983; 11(5):339-345.
80. Brinker JA, Weiss JL, Lappe DL, Rabson JL, Summer WR, Permutt S, et al. Leftward septal displacement during right ventricular loading in man. Circulation 1980;61(3):626-633.
81. Cecconi M, Johnston E, Rhodes A. What role does the right side of the heart play in circulation? Crit Care 2006;10(Suppl 3):S5.
82. Matthay MA, Broaddus VC. Fluid and hemodynamic management in acute lung injury. Semin Respir Crit Care Med 1994;15(4):271-288.
83. Moloney ED, Evans TW. Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome. Eur Respir J 2003;21(4):720-727.
84. Prewitt RM, McCarthy J, Wood LD. Treatment of acute low pressure pulmonary edema in dogs: relative effects of hydrostatic and oncotic pressure, nitroprusside, and positive end-expiratory pressure. J Clin Invest 1981;67(2):409-418.
85. Benzing A, Brautigam P, Geiger K, Loop T, Beyer U, Moser E. Inhaled nitric oxide reduces pulmonary transvascular albumin flux in patients with acute lung injury. Anesthesiology 1995;83(6):1153-1161.
86. Benzing A, Geiger K. Inhaled nitric oxide lowers pulmonary capillary pressure and changes longitudinal distribution of pulmonary vascular resistance in patients with acute lung injury. Acta Anaesthesiol Scand 1994;38(7):640-645.
87. Chan CM, Klinger JR. The right ventricle in sepsis. Clin Chest Med 2008;29(4):661-676, ix.
88. McNeil K, Dunning J, Morrell NW. The pulmonary physician in critical care. 13: The pulmonary circulation and right ventricular failure in the ITU. Thorax 2003;58(2):157-162.
89. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004;103(2):147-166.
90. Boxer LA, Allen JM, Schmidt M, Yoder M, Baehner RL. Inhibition of polymorphonuclear leukocyte adherence by prostacyclin. J Lab Clin Med 1980;95(5):672-678.
91. Gorog P, Kovacs IB. Prostacyclin is a more potent stimulator of thrombolysis than inhibitor of haemostasis. Haemostasis 1986;16(5):337-345.
92. Beghetti M, Reber G, de MP, Vadas L, Chiappe A, Spahr-Schopfer I, et al. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur Respir J 2002;19(3):518-524.
93. Burghuber OC, Silberbauer K, Haber P, Sinzinger H, Elliott M, Leithner C. Pulmonary and antiaggregatory effects of prostacyclin after inhalation and intravenous infusion. Respiration 1984;45(4):450-454.
94. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil- interactions: linking hemostasis and inflammation. Blood Rev 2007;21(2):99-111.
95. Aronoff DM, Peres CM, Serezani CH, Ballinger MN, Carstens JK, Coleman N, et al. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities. J Immunol 2007;178(3):1628-1634.
96. Greene R, Lind S, Jantsch H, Wilson R, Lynch K, Jones R, et al. Pulmonary vascular obstruction in severe ARDS: angiographic alterations after intravenous fibrinolytic therapy. AJR 1987;148(3):501-508.
97. Radermacher P, Buhl R, Santak B, Klein M, Kniemeyer HW, Becker H, et al. The effects of prostacyclin on gastric intramucosal pH in patients with septic shock. Intensive Care Med 1995;21(5):414-421.
98. Pittet JF, Lacroix JS, Gunning K, Laverriere MC, Morel DR, Suter PM. Prostacyclin but not phentolamine increases oxygen consumption and skin microvascular blood flow in patients with sepsis and respiratory failure. Chest 1990;98(6):1467-1472.
99. Bihari D, Smithies M, Gimson A, Tinker J. The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients. N Engl J Med 1987;317(7):397-403.
100. Gatecel C, Mebazaa A, Kong R, Guinard N, Kermarrec N, Mateo J, et al. Inhaled nitric oxide improves hepatic tissue oxygenation in right ventricular failure: value of hepatic venous oxygen saturation monitoring. Anesthesiology 1995;82(2):588-590.
101. Eichelbronner O, Reinelt H, Wiedeck H, Mezody M, Rossaint R, Georgieff M, et al. Aerosolized prostacyclin and inhaled nitric oxide in septic shock: different effects on splanchnic oxygenation? Intensive Care Med 1996;22(9):880-887.
102. Radermacher P, Santak B, Wust HJ, Tarnow J, Falke KJ. Prostacyclin and right ventricular function in patients with pulmonary hypertension associated with ARDS. Intensive Care Med 1990; 16(4):227-232.
103. Buwalda M, Ince C. Opening the microcirculation: can vasodilators be useful in sepsis? Intensive Care Med 2002;28(9):1208-1217.
104. Gerlach H, Keh D, Semmerow A, Busch T, Lewandowski K, Pappert DM, et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study.AmJ Respir Crit Care Med 2003;167(7):1008-1015.
105. Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis K Jr, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004; 291(13):1603-1609.
106. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxic respiratory failure in children and adults: a meta-analysis. Anesth Analg 2003;97(4):989-998.
107. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxemic respiratory failure in children and adults. Cochrane Database Syst Rev 2003(1):CD002787.
108. Payen D, Vallet B, Group d'étude du NO dans l'ARDS. Results of the French prospective multicentric randomized double-blind placebo-controlled trial on inhaled nitric oxide in ARDS [abstract]. Intensive Care Med 1999; 25(Suppl. 1):S166.
109. Abraham E, Park YC, Covington P, Conrad SA, Schwartz M. Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med 1996;24(1):10-15.
110. Abraham E, Baughman R, Fletcher E, Heard S, Lamberti J, Levy H, et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med 1999;27(8):1478-1485.
111. Bone RC, Slotman G, Maunder R, Silverman H, Hyers TM, Kerstein MD, et al. Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group. Chest 1989;96(1):114-119.
112. Holcroft JW, Vassar MJ, Weber CJ. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome: a prospective trial. Ann Surg 1986;203(4):371-378.
113. Rossignon MD, Khayat D, Royer C, Rouby JJ, Jacquillat C, Viars P. Functional and metabolic activity of polymorphonuclear leukocytes from patients with adult respiratory distress syndrome: results of a randomized double-blind placebo-controlled study on the activity of prostaglandin E1. Anesthesiology 1990;72(2):276-281.
114. Shoemaker WC, Appel PL. Effects of prostaglandin E1 in adult respiratory distress syndrome. Surgery 1986;99(3):275-283.
115. Vincent JL, Brase R, Santman F, Suter PM, McLuckie A, Dhainaut JF, et al. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med 2001;27(10):1578-1583.
116. Adhikari N, Burns KE, Meade MO. Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev 2004(4):CD004477.
117. Hess D, Bigatello L, Hurford WE. Toxicity and complications of inhaled nitric oxide. Respir Care Clin N Am 1997;3(4):487-503.
118. Hess DR. Adverse effects and toxicity of inhaled nitric oxide. Respir Care 1999;44(3):315-330.
119. Kirmse M, Hess D, Fujino Y, Kacmarek RM, Hurford WE. Delivery of inhaled nitric oxide using the Ohmeda INOvent Delivery System. Chest 1998;113(6):1650-1657.
120. Hess D, Ritz R, Branson RD. Delivery systems for inhaled nitric oxide. Respir Care Clin N Am 1997;3(3):371-410.
121. Imanaka H, Hess D, Kirmse M, Bigatello LM, Kacmarek RM, Steudel W, et al. Inaccuracies of nitric oxide delivery systems during adult mechanical ventilation. Anesthesiology 1997;86(3):676-688.
122. Nishimura M, Hess D, Kacmarek RM, Ritz R, Hurford WE. Nitrogen dioxide production during mechanical ventilation with nitric oxide in adults. Effects of ventilator internal volume, air versus nitrogen dilution, minute ventilation, and inspired oxygen fraction. Anesthesiology 1995;82(5):1246-1254.
123. Branson RD, Hess DR, Campbell RS, Johannigman JA. Inhaled nitric oxide: delivery systems and monitoring. Respir Care 1999; 44(3):281-306.
124. Van Dyke RE, Nikander K. Delivery of iloprost inhalation solution with the HaloLite, Prodose, and I-neb adaptive aerosol delivery systems: an in vitro study. Respir Care 2007;52(2):184-190.
125. Harris KW, O'Riordan TG, Smaldone GC. Aerosolized iloprost customized for the critically ill. Respir Care 2007;52(11):1507-1509.
126. van Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest 2000;117(3):819-827.
127. Meyer J, Theilmeier G, Van Aken H, Bone HG, Busse H, Waurick R, et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg 1998;86(4):753-758.
128. Dhand R. Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J Aerosol Med Pulm Drug Deliv 2008;21(1):45-60.
129. Dhand R, Guntur VP. How best to deliver aerosol medications to mechanically ventilated patients. Clin Chest Med 2008;29(2):277-296.
130. Dhand R. Bronchodilator therapy in mechanically ventilated patients: patient selection and clinical outcomes. Respir Care 2007; 52(2):152-153.
131. Dhand R. Inhalation therapy in invasive and noninvasive mechanical ventilation. Curr Opin Crit Care 2007;13(1):27-38.
132. Dhand R, Mercier E. Effective inhaled drug administration to mechanically ventilated patients. Expert Opin Drug Deliv 2007;4(1):47-61.